Investigators: Nick Gottardo, Raelene Endersby
Project description
SJELiOT is a phase 1 clinical trial that explores the combination of a new drug called LY2606368 with other chemotherapy drugs used to treat the childhood brain cancer medulloblastoma. We will determine the maximum dose that is safe to use in children in whom the disease has come back or does not respond to treatment. Also, a small group of patients will receive the identified safe combination dose to detect a preliminary signal that this new combination is effective at treating the disease.
Collaborators
- Giles Robinson
- Martine Roussel
- Amar Gajjar
- Clinton Stewart
- Tim Hassall
Partners
- Medical Research Future Fund